ACADIA Pharmaceuticals Inc
(MEX:ACAD)
MXN
362
(0%)
Market Cap: 75.95 Bil
Enterprise Value: 61.93 Bil
PE Ratio: 11.51
PB Ratio: 3.47
GF Score: 73/100 ACADIA Pharmaceuticals Inc at Citi Global Healthcare Conference Transcript
Dec 03, 2024 / 03:15PM GMT
Release Date Price:
MXN509
Yigal Nochomovitz
Citigroup Global Markets Inc. - Analyst
Okay. Great. All right. Welcome, everyone. I'm Yigal Nochomovitz, one of the biotech analysts here at Citigroup. Welcome to Miami, our first iteration of the conference down here in Florida. So it's my great pleasure to have with me senior leadership of ACADIA Pharmaceuticals. We have the CEO, Catherine Owen Adams. Welcome. Head of R&D, Liz Thompson; and Mark Schneyer, the CFO.
Mark Schneyer
ACADIA Pharmaceuticals Inc - Chief Financial Officer, Executive Vice President
Hello, Yigal.
Questions & Answers
Yigal Nochomovitz;Catherine Owen Adams
Citigroup Global Markets Inc. - Analyst;ACADIA Pharmaceuticals Inc - Chief Executive Officer, Director
Great. Great. Thank you so much for being here. So maybe we can just kick it off with just a high-level overview of the company, the products that you're selling where you are in the trajectory with the two products in the market, and we'll get into the pipeline later.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot